Multidrug resistant tuberculosis: risk factors and the application of innovative techniques for the rapid identification of resistances

Informations projet

N° de convention de subvention: BMH4972339

Projet clôturé

Date de début 1 Juillet 1997

Date de fin 30 Juin 2000

Financé au titre de

• Specific research, technological development and demonstration programme in the field of biomedicine and health, 1994-1998

Coût total

Aucune donnée

Contribution de l’UE

Aucune donnée

Coordonné par

LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH
Germany

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Method for the simple, rapid, and culture-independent detection of isoniazid, streptomycin and ethambutol resistance in mycobacteria

A rapid, culture-independent, and technically simple method has been developed for the prediction of isoniazid, streptomycin, ethambutol resistance in mycobacteria directly from clinical specimen (e.g. sputum). Background: The diagnostic detection of drug resistances in mycobacteria is impeded by the slow growth of many species, e.g. Mycobacterium tuberculosis. Resistance to the first-line therapeutic of these drugs can be predicted from specific mutations in resistance genes. Previous methods to detect these mutations were either too expensive and requiring special equipment, or little sensitive, requiring previous cultures. Key innovative features: Resistance-specific mutations are detected by PCR-RFLP, requiring only a PCR machine and a simple (minigel-) electrophoresis chamber. The technique is amenable to be marketed in a diagnostic kit format. Benefits: Any diagnostic laboratory with minimal technical equipment will be able to diagnose isoniazid resistance within 48 hours. This can be done without having to culture mycobacteria for which a special license and specific laboratory safety equipment would be needed. Current state of the art: The diagnostic detection of drug resistances in mycobacteria is impeded by the slow growth of many species, e.g. Mycobacterium tuberculosis. Resistance to the first-line therapeutic drug streptomycin can be predicted from specific mutations in resistance genes. Previous methods to detect these mutations were either too expensive and requiring special equipment, or little sensitive, requiring previous cultures. The improvement over the current state of the art is that resistance-specific mutations can be detected in a routine diagnostic setting by any microbiology laboratory, requiring only a PCR machine and a simple (minigel) electrophoresis chamber. The technique is amenable to be marketed in a diagnostic kit format.